Retrophin Company Profile (NASDAQ:RTRX)

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.67 (48.07% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016BMO Capital MarketsReiterated RatingOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Leerink SwannReiterated RatingBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Nomura Holdings Inc.Reiterated RatingBuy$31.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Avondale PartnersInitiated CoverageOutperform$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.50)($0.04)$17.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Retrophin (NASDAQ:RTRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline
07/22/16 06:01 PMNoteworthy Wednesday Option Activity: RUBI, RTRX, SCTY
07/22/16 09:08 AMRetrophin Incorporated (NASDAQ:RTRX) Shorted Shares Increased By 4.68% - Consumer Eagle
07/21/16 03:30 PMRetrophin to Report Second Quarter 2016 Financial Results - [GlobeNewswire] - SAN DIEGO, July 21, 2016-- Retrophin, Inc. today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will ...
07/21/16 07:13 AMRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : July 21, 2016 -
07/20/16 07:05 PMRetrophin (RTRX) Adds New Board member - StreetInsider.com
07/20/16 07:05 PMIncreased Stock Volatility Watch: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily
07/20/16 05:03 AMRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
07/19/16 03:30 PMRetrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors - [GlobeNewswire] - SAN DIEGO, July 19, 2016-- Retrophin, Inc. today announced the appointment of Roy D. Baynes, M.D., Ph.D., to its Board of Directors, effective immediately. Baynes currently serves as senior vice president ...
07/19/16 07:20 AMShare Performance Summary for: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph
07/19/16 07:20 AMShares Lower on the Year Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph
07/17/16 05:36 PMShares Experiencing a Downtrend: Retrophin, Inc. (NASDAQ:RTRX) - TGP
07/16/16 09:27 AMEven Under 'Worst Case Scenario,' BMO Thinks Retrophin Should Trade Higher
07/16/16 09:27 AMEx-drug exec Shkreli's U.S. fraud trial set for June 2017
07/15/16 05:12 PMRetrophin, Inc. (NasdaqGM:RTRX) Fundamental Star Rating Report - CML News
07/14/16 07:06 PMShkreli gets a year to figure out how to throw his ex-lawyer under the bus - Ars Technica - Ars TechnicaShkreli gets a year to figure out how to throw his ex-lawyer under the busArs TechnicaMartin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, exits federal court in New York, US, on Thursday, December 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011.Martin Shkreli May Blame His Old Lawyer for His Alleged CrimesVanity FairEx-drug executive Shkreli to face US fraud trial in June 2017ReutersShkreli, co-defendant likely to seek separate trials in fraud caseUSA TODAYNBCNews.com -CNBC -Bloomberg -CNNMoneyall 18 news articles »
07/14/16 06:30 PMEven Under 'Worst Case Scenario,' BMO Thinks Retrophin Should Trade Higher - Benzinga
07/14/16 04:24 PMDid Shkreli kill the biotech rally? -
07/14/16 03:35 PMEx-drug executive Shkreli to face U.S. fraud trial in June 2017 - [Reuters] - Martin Shkreli, the former pharmaceutical executive who last year became a lightning rod for criticism of soaring prescription drug prices, is now scheduled to go on trial in June 2017 in the U.S. government's securities fraud case against him. U.S. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli, 33, and Evan Greebel, a former lawyer for Retrophin Inc, a biopharmaceutical company which Shkreli founded and headed until 2014. The judge also set Oct. 2, 2017, for a potential second trial, after Brafman said he expected to file a severance motion so that Shkreli and Greebel could be tried separately.
07/14/16 01:24 PMAccused fraudster Martin Shkreli's trial set for June 26 -
07/13/16 09:07 AMStock Providing Gains on the Month for Investors: Retrophin, Inc. (NASDAQ:RTRX) - Telanagana Press
07/12/16 11:01 PMThe GOP Needs To Tackle The High Price Of Prescription Drugs -
07/12/16 06:28 PMRetrophin Inc. (RTRX): Scopia Capital Adds To Its Stake - Insider Monkey (blog)
07/12/16 12:55 PMRetrophin Inc. (RTRX): Scopia Capital Adds To Its Stake -
07/11/16 06:07 PMRetrophin Inc Realized Volatility Hits Extreme Level - CML News
07/11/16 06:07 PMStock Performance Rundown on: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph
07/11/16 06:07 PMRetrophin Inc (NASDAQ:RTRX) Institutional Investors Quarterly Sentiment - Press Telegraph
07/10/16 05:29 PMNext Weeks Broker Price Targets For Retrophin, Inc. (RTRX) - Fiscal Standard
07/08/16 06:13 PMRetrophin, Inc. (RTRX) Current Analyst Ratings - Fiscal Standard
07/07/16 06:17 PMShort Information Review for: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily
07/07/16 06:17 PMNew Broker Ratings For Retrophin, Inc. (RTRX) - FTSE News
07/04/16 05:21 PMThis Weeks Broker Price Targets For Retrophin, Inc. (RTRX) - Fiscal Standard
07/04/16 05:21 PMShare Performance Recap for: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph
07/02/16 05:45 PMRetrophin Incorporated (NASDAQ:RTRX) Short Interest Decreased By 2.66% - Engelwood Daily
06/30/16 09:02 AMShort Data Recap for: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily
06/30/16 09:02 AMRetrophin, Inc. (RTRX) Updated Price Targets - FTSE News
06/29/16 08:58 AMEndo's Stock Gains on Vasostrict's New Patent Approval
06/27/16 10:21 AMRetrophin, Inc. (RTRX) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 06:50 PMAnavex's Lead Candidate Gets Orphan Drug Status Yet Again
06/23/16 08:52 AMRetrophin (RTRX) Data Shows RE-024 Safe and Well Tolerated with Clinically Meaningful Improvements - StreetInsider.com
06/23/16 08:52 AMRetrophin Inc. (RTRX) is Trading Higher on Unusual Volume for June 21 - Equities.com
06/22/16 10:55 AMRetrophin (RTRX) Is Today's Strong On High Volume Stock - TheStreet.com
06/21/16 03:51 PMInovio Stock Up, Zika Vaccine Gets Nod for Phase I Study -
06/21/16 10:32 AMFate's (FATE) ProTmune Gets Fast Track Status, Stock Up
06/21/16 10:32 AMRetrophin (RTRX) to Acquire Usodeoxycholic Acid Rights from Asklepion Pharma in ~$24M Deal
06/21/16 05:03 AMRETROPHIN, INC. Files SEC form 8-K, Other Events -
06/20/16 05:55 PMRetrophin (RTRX) to Acquire Usodeoxycholic Acid Rights from Asklepion Pharma in ~$24M Deal - StreetInsider.com
06/20/16 05:55 PMThis Weeks Broker Views For Retrophin, Inc. (RTRX) - Fiscal Standard
06/20/16 03:59 PMRetrophin Acquires Liquid Formulation of Ursodeoxycholic Acid - [at noodls] - June 20, 2016 SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid ...
06/13/16 09:09 AMAgios Reports Favorable Phase II PK Deficiency Study Data
06/11/16 09:07 AMJune 24 Deadline Upcoming in Settlement in the Retrophin Inc (NASDAQ:RTRX) Investor Lawsuit

Social

About Retrophin

Retrophin logoRetrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RTRX
  • CUSIP:
Key Metrics:
  • Previous Close: $18.01
  • 50 Day Moving Average: $17.91
  • 200 Day Moving Average: $15.91
  • P/E Ratio: 9.38
  • P/E Growth: 11.09
  • Market Cap: $660.53M
  • Beta: 1.14
  • Current Year EPS Consensus Estimate: $0.08 EPS
  • Next Year EPS Consensus Estimate: $-0.27 EPS
Additional Links:
Retrophin (NASDAQ:RTRX) Chart for Tuesday, July, 26, 2016